菜单
Recommends initiating intravenous bisphosphonate or denosumab for adults with hypercalcemia of malignancy compared with no treatment. Use when a clinician asks about first‑line pharmacologic therapy for HCM or when deciding to start antiresorptive agents.
默认使用会先检查来源的 Prompt；你也可以切换为直接命令，或下载本地副本。
决定是否安装前，请先阅读 SKILL.md，以及 SkillsMP 当前展示的配套文件。
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
直接命令不会经过审查 Prompt；运行前请先检查来源。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill es-hcm-treat-bp-or-dmab命令会保持在同一行。复制前请横向滚动并检查完整内容。
想先保存到本地？可下载 SkillsMP 当前能够提供的文件。
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
基于 SOC 职业分类
正在显示 SKILL.md
| name | es-hcm-treat-bp-or-dmab |
| description | Recommends initiating intravenous bisphosphonate or denosumab for adults with hypercalcemia of malignancy compared with no treatment. Use when a clinician asks about first‑line pharmacologic therapy for HCM or when deciding to start antiresorptive agents. |
Confirm adult patient with malignancy-associated hypercalcemia: symptoms (fatigue, nausea, polyuria, etc.), serum calcium above upper limit of normal, underlying malignancy documented. Collect serum calcium (adjusted for albumin or ionized calcium), renal function (eGFR), malignancy type, and prior antiresorptive exposure.
If hypercalcemia is attributable to malignancy (HCM) and not to primary hyperparathyroidism, vitamin D excess, or other non‑malignant causes, proceed to treatment; otherwise, pursue alternative diagnosis and do not initiate antiresorptive therapy for HCM.
Assess renal function to guide agent selection: if eGFR <30 mL/min/1.73 m², prefer denosumab; if eGFR ≥30 mL/min/1.73 m², either intravenous bisphosphonate (pamidronate or zoledronic acid) or denosumab may be used.
Administer intravenous bisphosphonate (pamidronate 60–90 mg IV over 2–24 hours or zoledronic acid 4 mg IV over 15 minutes) or denosumab 120 mg subcutaneously, based on renal function and drug availability.
Do not use in patients without malignancy‑associated hypercalcemia; avoid in severe uncorrected hypocalcemia; monitor serum calcium and renal function after infusion; avoid rapid calcium correction that may precipitate arrhythmias; do not rely solely on antiresorptives in severe HCM without considering adjunct calcitonin for immediate calcium reduction; avoid in patients with known hypersensitivity to bisphosphonates or denosumab.
A 62‑year‑old woman with metastatic breast cancer presents with fatigue and nausea; serum calcium 13.8 mg/dL (albumin 4.0 g/dL). Malignancy confirmed, eGFR 45 mL/min/1.73 m², no prior bisphosphonate. Initiate zoledronic acid 4 mg IV over 15 minutes.
Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, DOI: 10.1210/clinem/dgac621